Compositions and methods for the detection diagnosis and therapy of hematological malignancies

Abstract

Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

1 - 16 . (canceled) 
     
     
         17 . A method for treating cancer in a mammalian subject wherein a B-cell from the subject overexpresses SEQ ID NO:4 comprising, administering to the subject an effective amount of an antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4, wherein the cancer is multiple myeloma. 
     
     
         18 . The method of  claim 17 , wherein the antibody is a humanized antibody. 
     
     
         19 . The method of  claim 17 , wherein the antibody is a monoclonal antibody. 
     
     
         20 . The method of  claim 17 , wherein the mammalian subject is a human. 
     
     
         21 . The method of  claim 17 , wherein administration is intravenous. 
     
     
         22 . The method of  claim 17 , wherein the antibody is coupled to a therapeutic agent. 
     
     
         23 . The method of  claim 22 , wherein the therapeutic agent is a cytotoxic agent. 
     
     
         24 . The method of  claim 22 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         25 . The method of  claim 22 , wherein the therapeutic agent is coupled to the antibody via a linker. 
     
     
         26 . The method of  claim 17 , wherein the antibody is an immunotherapeutic antibody. 
     
     
         27 . The method of  claim 26 , wherein the antibody is a passive immunotherapeutic antibody. 
     
     
         28 . The method of  claim 27 , wherein the passive immunotherapeutic antibody directly or indirectly mediates antitumor effect and does not necessarily depend on an intact host immune system. 
     
     
         29 . The method of  claim 26 , wherein the antibody is an active immunotherapeutic antibody. 
     
     
         30 . The method of  claim 29 , wherein the active immunotherapeutic antibody relies on in vivo stimulation of the endogenous host immune system against the cancer cells.